Imfinzi plus Imjudo approved in the EU for patients with 1L HCC and mNSCLC based on significant survival benefits in HIMALAYA and POSEIDON Ph 3 trials February 28, 2023
Pivotal Ph 3 IMbrave050 trial of Tecentriq + Avastin in people with early-stage HCC at high risk of recurrence following surgery met primary endpoint of RFS February 1, 2023
ASCO GI: Final Results and New Xerna™ TME Panel Biomarker Data from Ph 2 Trial of Bavituximab + Pembrolizumab in 1L HCC Patients announced February 1, 2023
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers January 4, 2023
Adagene and Roche to Evaluate SAFEbody® ADG126 in Combination with Standard-of-Care for 1L HCC December 19, 2022
Adagene and Roche to Evaluate ADG126 in Combination with Atezolizumab & Bevacizumab for 1L Advanced HCC December 17, 2022
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In CRC and HCC December 13, 2022
Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial November 16, 2022
Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer based on Ph 3 HIMALAYA trial November 2, 2022
Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option Announced October 19, 2022
Camrelizumab + Rivoceranib (Apatinib) Significantly Prolonged OS & PFS vs Sorafenib in Patients with uHCC in a Multinational Ph 3 Trial September 13, 2022
Results From Ph 3 LEAP-002 Trial of KEYTRUDA® + LENVIMA® Versus LENVIMA Monotherapy in Patients With uHCC presented September 13, 2022
Tislelizumab demonstrated efficacy and tolerability in 1L advanced liver cancer in Ph 3 RATIONALE 301 trial September 13, 2022
